Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks ( (ZYME) ) just unveiled an update.
On May 7, 2026, Zymeworks reported first-quarter 2026 results and a corporate update, highlighting $403.8 million in cash, cash equivalents and marketable securities as of March 31, 2026, and noting it has deployed $95.8 million under a $125 million share repurchase program, buying 3.93 million shares and reducing outstanding stock to roughly 73 million. The company reiterated disciplined non-GAAP operating expense guidance through 2028 and strengthened its leadership bench with new executives in finance, R&D, business development and legal.
Operationally, Zymeworks’ partner Jazz secured U.S. FDA Priority Review in April 2026 for zanidatamab in first-line HER2-positive advanced gastroesophageal adenocarcinoma with an August 25, 2026 PDUFA date, and China’s NMPA accepted a similar filing via partner BeOne, positioning Zymeworks for sizable U.S. and China approval milestones and long-term royalties. Zymeworks also reported positive updated Phase 1 data for its wholly owned ADC ZW191 in platinum-resistant ovarian and endometrial cancers, presented new RAS inhibitor ADC platform candidates at AACR, and recorded $1.6 million in first-quarter 2026 royalty revenue from Jazz and BeOne, underscoring a growing royalty-based business model alongside internal pipeline development.
The most recent analyst rating on (ZYME) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Overall score reflects a strong earnings-call outlook (clinical validation, regulatory path, improved FY2025 performance, and nondilutive financing) offset by weak underlying financial performance (recent losses and ongoing cash burn) and neutral technicals; valuation remains challenged due to unprofitability (negative P/E).
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a Nasdaq-listed biotechnology company that manages a portfolio of licensed healthcare assets while developing a diversified pipeline of novel, multifunctional biotherapeutics, including antibody-drug conjugates. The company focuses on oncology, advancing candidates such as zanidatamab for HER2‑positive cancers and ZW191 for ovarian and endometrial tumors, and derives revenue from milestones, royalties, and partnered programs.
Average Trading Volume: 632,521
Technical Sentiment Signal: Buy
Current Market Cap: $2.05B
See more data about ZYME stock on TipRanks’ Stock Analysis page.